β-arrestin 1(ARRB1), as a well-known primary effector of the GPCR pathway, has been shown to promote several stages in the progression of different cancers, including leukaemia, breast cancer, lung cancer, colon cancer and laryngeal carcinoma 7. This evidence concerns the gene ARRB1 and lung carcinoma.